4-(pyrrolidine-1-carbonyl)phenylboronic acid
Product Information
Molecular Formula
C11H14BNO3
Molecular Weight
219.04
Description
4-(Pyrrolidine-1-carbonyl)phenylboronic acid is a highly significant compound extensively utilized in the biomedical field and showcases remarkable potential in the amelioration of diverse ailments. Cancer, diabetes, and disorders associated with inflammation are among the targeted conditions that this product exhibits promising outcomes in treating. Capitalizing on its distinctive chemical configuration, it possesses immense prospects for spearheading the innovation of revolutionary therapeutic interventions.
Synonyms
4-(Pyrrolidine-1-carbonyl)phenyl)boronic acid; 4-Pyrrolidinylcarbonylphenylboronic acid; [4-(pyrrolidine-1-carbonyl)phenyl]boronic Acid; 4-[(PYRROLIDIN-1-YL)CARBONYL]BENZENEBORONIC ACID; [4-(pyrrolidin-1-ylcarbonyl)phenyl]boronic acid; 4-(pyrrolidine-1-carbonyl)phenyboronic acid; DB-032405; 4(pyrrolidin-1-ylcarbonyl)phenylboronic acid; 4-pyrrolidine-1-carbonyl phenyl boronic acid; 4-(pyrrolidin-1-ylcarbonyl)phenylboronic acid; [4-(1-pyrrolidinylcarbonyl)phenyl]boronic acid; 4-(Pyrrolidine-1-carbonyl)-phenyl boronic acid; 4-[(1-Pyrrolidinyl)carbonyl]phenylboronic Acid; 4-(pyrrolidine-1-carbonyl)phenylboronic acid; [4-(Pyrrolidine-1-carbonyl)phenyl]boronic acid
IUPAC Name
[4-(pyrrolidine-1-carbonyl)phenyl]boronic acid
SMILES
B(C1=CC=C(C=C1)C(=O)N2CCCC2)(O)O
InChI
InChI=1S/C11H14BNO3/c14-11(13-7-1-2-8-13)9-3-5-10(6-4-9)12(15)16/h3-6,15-16H,1-2,7-8H2
InChI Key
VKPBESPVHGDDJS-UHFFFAOYSA-N
Flash Point
Not applicable
Safety Information
Hazards
H319
Precautionary Statement
P305 + P351 + P338
Computed Properties
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
2
Exact Mass
219.1066735 g/mol
Monoisotopic Mass
219.1066735 g/mol
Topological Polar Surface Area
60.8Ų
Heavy Atom Count
16
Formal Charge
0
Complexity
246
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| WO-2020231990-A1 | Fgfr inhibitors and methods of use thereof | 2019-05-13 |
| AU-2020274083-A1 | FGFR inhibitors and methods of use thereof | 2019-05-13 |
| CN-114126620-A | FGFR inhibitors and methods of use thereof | 2019-05-13 |
| KR-20220007889-A | FGFR inhibitors and methods of use thereof | 2019-05-13 |
| AU-2018388404-A1 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | 2017-12-22 |
| WO-2019126731-A1 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | 2017-12-22 |
| BR-112020012635-A2 | aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | 2017-12-22 |
| EP-3728228-A1 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | 2017-12-22 |
| JP-2021506978-A | Aminopyridine derivative as phosphatidylinositol phosphate kinase inhibitor | 2017-12-22 |
| US-2021317136-A1 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | 2017-12-22 |
